超越粉样蛋白:用于阿尔茨海默病的纳米体介导的神经炎症疗法
Soukaina Amniouel1, Jessica Suh1, Wei Zheng1
1Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 20892, USA.
Translational neurodegeneration
|October 14, 2025
概括
本综述提出了一种新的阿尔茨海默病 (AD) 治疗方法,将单域抗体 (sdAbs) 与抗炎药物结合起来,同时向粉样质斑块和神经炎症,旨在提高阿尔茨海默病患者的疗效和减少副作用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 斑块,团和神经炎症,导致认知能力下降.
- 目前的抗粉样蛋白治疗可以增加炎症,并且有效性有限.
- 现有的疗法不能充分解决AD的神经炎症组成部分.
研究的目的:
- 引入一种针对阿尔茨海默病的新型免疫调节疗法.
- 将针对Aβ纤维的单域抗体 (sdAbs) 与抗炎药物结合起来.
- 专门针对斑块部位的神经炎症,调节微质细胞和天体细胞活动.
主要方法:
- 使用单域抗体 (sdAbs) 和抗炎药物的治疗策略的审查.
- 讨论sdAb的特征:小尺寸,组织透,缺乏Fc介导反应.
- 探索潜在的有效载荷 (小分子,生物制剂,纳米粒子) 和针对性治疗的输送系统.
主要成果:
- 拟议的治疗旨在改善Aβ清除,同时管理神经炎症.
- 它旨在控制激活的微质细胞和星球细胞,而不会导致广泛的免疫抑制.
- 这种方法提供了一个有希望的策略,以提高阿尔茨海默病的治疗疗效.
结论:
- 结合sdAb和抗炎药物治疗,为阿尔茨海默病提供了一个有前途的治疗方法.
- 针对粉样质斑块和神经炎症,可以克服当前治疗方法的局限性.
- 这一策略有可能改善阿尔茨海默病管理中的患者结果.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.2K
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
